Menu
Recruiting NCT03978039

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

— Observational Sarcoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Chemotherapy, Immunotherapeutic Agent, target treatment, Surgery.
Who it may be relevant to
Registry conditions: Sarcoma. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The "BCB-sarcomes" Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas

Overview

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples. Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes. With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).

Interventions

  • Drug Chemotherapy
    treatment as per standard of care
  • Drug Immunotherapeutic Agent
    treatment as per standard of care
  • Drug target treatment
    treatment as per standard of care
  • Procedure Surgery
    treatment as per standard of care
  • Radiation Radiotherapy
    treatment as per standard of care

Primary outcome measures

  • Time to next treatment (TNT) [Time frame: 2 years]
  • Time to next treatment (TNT) [Time frame: 5 years]
  • Overall survival (OS) [Time frame: 2 years]
  • Overall survival (OS) [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Diagnosis of sarcoma
  • Diagnosis in a French Comprehensive Cancer Center
  • Any age

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 3 centers
  • Institut Bergonié, Comprehensive Cancer Center — Bordeaux
  • Centre Léon Bérard — Lyon
  • Institut Gustave Roussy, Comprehensive Cancer Center — Villejuif

Publications

  • Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honore C, Sargos P, Sunyach MP, Le Pechoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s1 PMID 28391775
  • Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le Cesne A, Le Pechoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchere-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicen PMID 24567518
  • Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetiere F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board i PMID 29117335

Identifiers

NCT: NCT03978039 · IB2012-BCB-SARCOMES

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗